The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and risin ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of ...

Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

A new study has identified a critical mechanism that could lead to substantial advancements in the treatment of acute myeloid ...

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

First discovered by the laboratories of Victor Ambros and Gary Ruvkun in Caenorhabditis elegans, microRNAs (miRNAs) are the first extensively studied class of noncoding RNA. 1, 2 There are between ...

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...